SEC Comment Letter 0000000000-25-003480 to Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc.
Date: April 1, 2025 · CIK: 0001419041 · Accession: 0000000000-25-003480
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286226
Letter
Re: Forte Biosciences, Inc. Registration Statement on Form S-3 Filed March 28, 2025 File No. 333-286226 Dear Paul Wagner Ph.D.:
April 1, 2025
Paul Wagner, Ph.D. Chairman and Chief Executive Officer Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, TX 75247
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Dan Koeppen, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2025 Paul Wagner, Ph.D. Chairman and Chief Executive Officer Forte Biosciences, Inc. 3060 Pegasus Park Drive, Building 6 Dallas, TX 75247 Re: Forte Biosciences, Inc. Registration Statement on Form S-3 Filed March 28, 2025 File No. 333-286226 Dear Paul Wagner Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Dan Koeppen, Esq. </TEXT> </DOCUMENT>